- Details
- Alicia Morgans interviews Andre Esteva about ArteraAI's expanded prostate cancer test, now validated for low-risk and active surveillance patients. Dr. Esteva explains that the AI-driven test helps clinicians decide between active surveillance and definitive treatment by assessing the risk of adverse pathology at prostatectomy. The test, which uses digital pathology to analyze H&E slides without c...
|
- Details
- Asunción Hervás disccusses the HYPORT-ES trial, which examines hypofractionated postoperative radiotherapy in prostate cancer. Dr. Hervás discusses the phase II trial's design, which evaluated the efficacy and toxicity of moderate hypofractionation (62.5 Gy in 25 fractions) for adjuvant and salvage radiotherapy. The study, involving 405 patients from 23 Spanish centers, shows low rates of acute an...
|
- Details
- Ruchika Talwar interviews Brian Lane about a MUSIC collaborative study on same-day discharges for radical prostatectomy patients in Michigan. Dr. Lane discusses the study's findings, which show that only 2.8% of patients had same-day discharges between 2018 and 2022, despite efforts to increase uptake. The study demonstrates that same-day discharge is safe, with readmission rates comparable to one...
|
- Details
- Zachary Klaassen interviews Alison Tree about the PACE-C trial, comparing moderate hypofractionation to stereotactic body radiotherapy (SBRT) in unfavorable and high-risk prostate cancer patients. Dr. Tree discusses the trial design, which randomized 1,208 men to receive either standard 60 Gy in 20 fractions over four weeks or SBRT with 36.25-40 Gy in five fractions. The acute toxicity results sho...
|
- Details
- Oliver Sartor and Ken Herrmann discuss the current state and future directions of PSMA ligand therapy in prostate cancer treatment. Dr. Herrmann presents recent findings from various clinical trials, including PSMAfore and ENZA-p, which explore the use of lutetium-PSMA therapy in different stages of prostate cancer. They examine the potential of combining lutetium-PSMA with other treatments like e...
|
- Details
- E David Crawford interviews Jason Efstathiou about the PARTIQoL trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. The trial, involving 450 patients from 29 centers, focuses on patient-reported outcomes, particularly bowel function at 24 months. Dr. Efstathiou presents the study's design, methodology, and key findings. The results show no significant diff...
|
- Details
- Jason Efstathiou about the results of the PARTIQoL Trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou reveals that the study found no significant differences in tumor control or patient-reported quality of life between the two treatment modalities for low and intermediate-risk prostate cancer patients. He emphasizes the importance of this f...
|
- Details
- Duncan Gilbert discusses the PATCH trial, comparing transdermal estradiol with LHRH agonists for androgen suppression in non-metastatic prostate cancer. Dr. Gilbert discusses the trial design, which randomized 1,360 men to receive either transdermal estradiol patches or LHRH analogues. The primary results show non-inferiority of transdermal estradiol for metastasis-free survival and overall surviv...
|
- Details
- Jason Efstathiou discusses the PARTIQoL trial, a randomized phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou discusses the history and potential benefits of proton therapy, as well as the challenges in conducting comparative studies. He describes the trial design, which focuses on patient-reported outcomes, particularly bowel function at 24 months...
|
- Details
- Arnav Srivastava discusses his research on out-of-pocket costs for prostate cancer screening follow-up among privately insured men. The study reveals that by 2020, 80% of patients face out-of-pocket expenses for diagnostic testing, with costs rising significantly over time. Patients undergoing both MRI and biopsy can expect to pay over $600. Dr. Srivastava highlights the potential implications, in...
|
